Nataliya V. Uboha

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 225 citations · Full text

Medicine, Previous Pd, Bronchial Neoplasm +5

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with <i>KRAS</i> G12C-Mutated Metastatic Colorectal Cancer

Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster et al. · Cancer Discovery · 2024 · 88 citations · Full text

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · Journal of the National Comprehensive Cancer Network · 2025 · 72 citations

Cancer Management, Gastroenterology, Pathology +16

A Calcium- and Calmodulin-Dependent Kinase Iα/Microtubule Affinity Regulating Kinase 2 Signaling Cascade Mediates Calcium-Dependent Neurite Outgrowth

Nataliya V. Uboha, Marc Flajolet, Angus C. Nairn et al. · Journal of Neuroscience · 2007 · 68 citations · Full text

Molecular Regulation, Synaptic Transmission, Cytoskeleton +20

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

Nataliya V. Uboha, Mohammed Milhem, Christina Kovacs et al. · Journal of Clinical Oncology · 2019 · 59 citations

Immunology, Pathology, Phase Ii Study +17